Pharmaceuticals

MSI-H And dMMR Sector Forecast Shows Robust Momentum, Climbing to $21.13 Billion With 22.7% CAGR

February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the msi-h and dmmr market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the MSI-H And dMMR Market in 2026, and what figure is it projected to hit by 2030?

The msi-h and dmmr market has witnessed substantial expansion in recent years. It is projected to grow from $7.57 billion in 2025 to $9.32 billion in 2026, registering a compound annual growth rate (CAGR) of 23.1%. This historical growth can be ascribed to factors such as the discovery of msi-h and dmmr biomarkers, the initial success of immune checkpoint inhibitors, a rising incidence of colorectal and endometrial cancer, the expansion of molecular diagnostics, and regulatory approvals for biomarker-based therapies.

The msi-h and dmmr market is projected for significant expansion in the coming years, expected to reach $21.13 billion by 2030, propelled by a compound annual growth rate (CAGR) of 22.7%. This anticipated growth during the forecast period is primarily driven by factors such as the increasing adoption of precision oncology, wider utilization of genomic testing in cancer treatment, the broadening of immunotherapy applications, heightened investment in biomarker research, and the accumulation of clinical evidence favoring tumor-agnostic strategies. Key trends anticipated within this period encompass the growing embrace of immunotherapy for msi-h and dmmr tumors, greater reliance on companion diagnostics for patient classification, an elevated focus on tumor-agnostic cancer therapies, the proliferation of combination immunotherapy regimens, and enhanced recognition of biomarker-driven oncology.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp

Which Drivers Are Affecting Market Participation In The MSI-H And dMMR Market?

The increasing occurrence of cancer is anticipated to drive expansion in the MSI-H and dMMR market moving ahead. Cancer is defined as a collection of illnesses marked by the unregulated proliferation and dissemination of atypical cells throughout the body. This increase in cancer prevalence mainly stems from aging demographics, given that the likelihood of developing cancer substantially rises with advancing age, owing to the cumulative impact of genetic alterations and extended exposure to various risk factors over a period. Within cancer contexts, MSI-H and dMMR markers are utilized to pinpoint tumors exhibiting elevated mutation rates, which result from deficiencies in DNA repair systems. These biological markers assist in directing immunotherapy choices, since these particular tumors show a greater propensity to react to immune checkpoint inhibitors, and concurrently, they offer valuable information regarding patient prognosis and possible genetic syndromes. For example, as reported in January 2024 by the American Cancer Society, a US-based non-profit organization, projections for 2023 indicated that the United States would see an estimated 1,958,310 new cancer diagnoses and 609,820 fatalities linked to cancer. These figures are forecasted to climb in 2024, with an approximate 2,001,140 new cancer cases and 611,720 deaths predicted, underscoring an ongoing upward trend in both cancer occurrence and mortality rates. Consequently, the growing incidence of cancer is propelling the expansion of the MSI-H and dMMR market.

What Segment Categories Are Covered In The MSI-H And dMMR Market?

The msi-h and dmmr market covered in this report is segmented –

1) By Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy

2) By Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, Other Indications

3) By Stage: Early Stages, Advanced Stages

4) By End User: Hospitals, Oncology Clinics, Research Institutions, Homecare

Subsegments:

1) By Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, Cytotoxic T-Lymphocyte Antigen 4 Inhibitors

2) By Combination Therapy: Immune Checkpoint Inhibitor + Chemotherapy, Immune Checkpoint Inhibitor + Targeted Therapy, Immune Checkpoint Inhibitor + Radiation Therapy, Immune Checkpoint Inhibitor + Other Immunotherapies

What Trends Are Driving The Growth Trajectory Of The MSI-H And dMMR Market?

Leading companies operating in the MSI-H and dMMR market are concentrating on developing innovative treatments, such as combination therapy, to enhance treatment efficacy and improve patient outcomes. Combination therapy for MSI-H and dMMR cancers involves utilizing two or more treatment modalities, commonly including immunotherapy agents like checkpoint inhibitors or combining immunotherapy with chemotherapy, targeted therapy, or radiation. This approach aims to boost treatment response, overcome resistance, and improve survival outcomes in patients with tumors exhibiting high microsatellite instability or deficient mismatch repair. For instance, in April 2025, Bristol-Myers Squibb Company, a US-based pharmaceutical company, received United States Food and Drug Administration (FDA) approval for the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) features, further advancing therapeutic options for this challenging cancer subtype. This approval signifies a major milestone in the treatment of MSI-H and dMMR cancers, as it introduces a new, effective therapeutic option that targets multiple pathways to improve patient survival and response rates, thereby addressing the unmet medical needs in this patient population.

Which Major Industry Participants Are Leading The MSI-H And dMMR Market Growth?

Major companies operating in the msi-h and dmmr market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The MSI-H And dMMR Market?

North America was the largest region in the MSI-H and dMMR market in 2025. The regions covered in the msi-h and dmmr market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized MSI-H And dMMR Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24324&type=smp

Browse Through More Reports Similar to the Global MSI-H And dMMR Market 2026, By The Business Research Company

Automotive Human Machine Interface Hmi Market Report 2026

https://www.thebusinessresearchcompany.com/report/automotive-human-machine-interface-hmi-global-market-report

Electronic Data Interchange Edi Software Market Report 2026

https://www.thebusinessresearchcompany.com/report/electronic-data-interchange-edi-software-global-market-report

Digital Aerospace Mro Market Report 2026

https://www.thebusinessresearchcompany.com/report/digital-aerospace-mro-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795